ACTON, Mass. — Insulet Corp. has begun the U.S. rollout of an enhanced algorithm for its Omnipod 5 Automated Insulin Delivery System and expanded the device’s compatibility with Abbott’s FreeStyle Libre 3 Plus sensor.
The Acton-based company said the algorithm update follows FDA 510(k) clearance in December 2025 and is designed to improve automation, reduce interruptions and give people with diabetes more flexibility in managing their care.
The enhanced Omnipod 5 algorithm adds a new 100 mg/dL Target Glucose option, expanding available settings to six levels ranging from 100 mg/dL to 150 mg/dL. Insulet said the added setting gives healthcare providers more flexibility to personalize treatment and help users improve time in range.
“Delivering innovations that make diabetes management easier is at the heart of everything we do. These enhancements deliver what users tell us matters most—smarter automation, more personalization, better control, and expanded choice,” said Eric Benjamin, Insulet Executive Vice President and Chief Operating Officer. “By offering a lower target glucose option and expanding sensor compatibility, we’re helping people spend less time making decisions about diabetes and more time feeling confident, supported, and in control.”
Insulet said real-world evidence shows that lowering Target Glucose can increase time in range without a clinically meaningful increase in time below range. The company said the updated algorithm also helps users remain in Automated Mode longer, including during prolonged high-glucose events.
The company began shipping compatible Pods into U.S. retail channels before the rollout to help users access the new 100 mg/dL Target Glucose feature. Existing Omnipod 5 users will receive an over-the-air software update through their Omnipod 5 Controller or mobile app, with access expanding as compatible Pods become available.
Insulet also said Omnipod 5 is now compatible in the U.S. with Abbott’s Libre 3 Plus sensor. The integration allows caregivers to follow patients through Abbott’s LibreLinkUp app and is intended to give users more choice in continuous glucose monitoring options when using automated insulin delivery.
The company said additional international rollouts are planned later this year.
Insulet is expected to share more information about the update during the American Diabetes Association’s 86th Scientific Sessions, scheduled for June 5-8, 2026, in New Orleans.
Omnipod 5 automatically adjusts insulin delivery every five minutes and is designed to reduce the need for multiple daily injections. The system is cleared in the U.S. for people age 2 and older with type 1 diabetes and adults age 18 and older with type 2 diabetes.
